Virtual controls in preclinical toxicity testing are now well known. In the Translational Medicine Unit (TMU) at the Sanofi BioCampus in Frankfurt, for example, Dr. Markus Rehberg is taking it a step further by developing digital twins for clinical drug development using quantitative systems pharmacology (QSP) models.
Modeling using quantitative systems pharmacology (QSP) enables drug developers to simulate thousands of experiments, clinical trials, and alternative hypotheses using in silico methods before conducting costly experiments. QSPs are mathematical and computer-based simulation tools that combine systems biology and pharmacology.
Read more here:
1. https://info.metrumrg.com/en/qsp-1
2. https://www.bionity.com/de/news/1188928/wirkstoffforschung-mit-virtuellen-patienten.html? utm_source=newsletter&utm_medium=email&utm_campaign=bionityde--2026-06-15--1&mtm_group=bionityde&WT.mc_id=ca0264
3. Musante CJ, Ramanujan S, Schmidt BJ, Ghobrial OG, Lu J, Heatherington AC. Quantitative Systems Pharmacology: A Case for Disease Models. Clin Pharmacol Ther. 2017 Jan;101(1):24-27. doi: 10.1002/cpt.528. Epub 2016 Nov 18. PMID: 27709613; PMCID: PMC5217891.
-
font size
decrease font size
increase font size
Tuesday, 16 June 2026 14:47
Frankfurt: Drug development involving virtual patients Featured
Quantitative Systems Pharmacology (QSP) models play a central and increasingly important role in clinical development. They combine biology, pharmacology, and mathematics to simulate the interactions between drugs and the complex human biological system on a computer.
Dr. rer. nat.
Menschen für Tierrechte - Tierversuchsgegner Rheinland-Pfalz e.V.